GlassScriptPhysician profile
Mark F Torres
NPI 1255399457
$2,586.20
in general payments reported to CMS, 2019-2025
9 companies · $244 in 2025
The $244 reported for 2025 was less than what a typical Ophthalmology provider received nationally (typical 2025 total: $384).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $287 · 2020: $594 · 2021: $460 · 2022: $314 · 2023: $651 · 2024: $35.84 · 2025: $244.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $931.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $931.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Alcon Vision LLC | $1,215.90 | 2019-2025 | Clareon, Argos |
| Carl Zeiss Meditec USA, INC. | $658.52 | 2021-2023 | Cirrus Hd-Oct, Iolmaster 700 |
| Carl Zeiss Meditec, INC. | $253.50 | 2019-2020 | |
| Rayner Intraocular Lenses Limited | $161.52 | 2023-2025 | Rayone Aspheric, Rayone Emv, Rayone Spheric |
| Johnson & Johnson Surgical Vision, INC. | $109.04 | 2020 | |
| Beaver-Visitec International, INC. | $72.55 | 2022 | |
| Glaukos Corporation | $40.00 | 2021 | |
| Carl Zeiss Meditec Ag | $38.80 | 2020 | |
| Sight Sciences, INC. | $36.37 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Mark Torres listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.